Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced results of retrospective sub-analyses from a Phase III, open-label study designed to compare the impact of two anemia management strategies – ribavirin dose reduction and an investigational use of erythropoietin (EPO) – on sustained virologic response (SVR)1 in patients with chronic hepatitis C virus (HCV) genotype 1 infection treated with VICTRELIS® (boceprevir) 200 mg Capsules in combination with peginterferon alfa and ribavirin (PR). These data will be presented this week at The American Association for the Study of Liver Diseases 2012 Annual Meeting (AASLD).
In the sub-analysis evaluating eligible patients who were randomized to receive ribavirin dose reduction for anemia management, SVR rates were generally similar regardless of when patients began ribavirin dose reduction, the number of steps of ribavirin dose reduction, or the lowest ribavirin dose of 400 to 1,000 mg/day received for at least 14 days for anemia management. However, SVR rates were lower in patients who received less than 50 percent of their total assigned dose of ribavirin compared to those who received at least 50 percent of their assigned dose. SVR rates were higher in those patients who had undetectable HCV RNA than those who had detectable HCV RNA at the start of their anemia management intervention, and these respective SVR rates were the same regardless of anemia management strategy.
“These analyses further confirm that ribavirin dose reduction should be the primary strategy for managing anemia in patients taking VICTRELIS combination therapy, including cirrhotic patients,” said Fred Poordad, M.D., chief medical officer, Alamo Medical Research, and professor of medicine at the University of Texas Health Science Center, San Antonio.
Indications and usage for VICTRELIS (boceprevir)
VICTRELIS is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 (G1) infection, in combination with peginterferon alfa and ribavirin (PR), in adult patients (18 years and older) with compensated liver disease, including cirrhosis, who are previously untreated or who have failed previous interferon and ribavirin therapy.
The following points should be considered when initiating VICTRELIS for treatment of chronic HCV infection:
About the Study
The primary endpoint of the study was the comparison of SVR in patients who were randomized to receive ribavirin dose reduction or the addition of EPO, and those results were presented at the European Association for the Study of the Liver (EASL) 2012 annual meeting. The rates of SVR were 71 percent for both groups: those patients whose anemia was managed by ribavirin dose reduction (178/249) and those patients whose anemia was managed by the addition of EPO (178/251). The rates of relapse were 10 percent in both groups.
In this study, 687 treatment-naïve adult patients with chronic HCV genotype 1 who had baseline hemoglobin levels at least 12 g/dL for females and at least 13 g/dL for males, but less than or equal to 15 g/dL were enrolled in a randomized, multinational, open-label trial and monitored for the development of anemia. Patients were treated with a 4-week lead-in of peginterferon alfa-2b (1.5 mcg/kg/week) and an investigational dose of weight-based ribavirin (600-1,400 mg/day), followed by the addition of VICTRELIS (boceprevir) (800 mg three times a day) after week 4 for 24 or 44 weeks based on response-guided therapy. Patients with compensated cirrhosis were allowed (METAVIR fibrosis score of F1-F4) provided they had no other concurrent liver diseases. Patients with HIV or hepatitis B virus were excluded.
A total of 500 patients developed anemia, defined by having hemoglobin of approximately less than or equal to 10 g/dL. Patients with anemia were randomized to receive either ribavirin dose reduction (by 200 mg/d [or 400 mg/d if the initial ribavirin dose was 1,400 mg/d]) or the addition of EPO (starting at 40,000 units/week, but could be modified at the investigator's discretion to doses of 20,000 – 60,000 units/week). A secondary method of anemia management, such as the addition of EPO or ribavirin dose reduction was later permitted if a patient's hemoglobin reached less than or equal to 8.5 g/dL. Treatment was discontinued if hemoglobin levels reached less than or equal to 7.5 g/dL.
Impact of timing and magnitude of ribavirin dose reduction on SVR
In the ribavirin dose reduction arm, SVR rates were generally similar regardless of when patients began ribavirin dose reduction, the number of steps of ribavirin dose reduction, or the lowest ribavirin dose of 400 to 1,000 mg/day received for at least 14 days for anemia management. There were few patients, ranging from 3 to 12 in each subgroup, in the ribavirin dose reduction arm who received the lowest ribavirin doses outside the range of 400 to 1,000 mg/day for at least 14 days.
* One step = decrease of 200 mg ribavirin per day for greater than or equal to 3 days
*Lowest ribavirin dose (mg/day) received for at least 14 days during the treatment period based on information in patient diaries.
This sub-analysis included small numbers of patients in some subgroups. Patients were not randomized into subgroups so there could be baseline differences that affected the results.
Impact of HCV-RNA levels at start of anemia management intervention on SVR
The SVR rates for patients with undetectable levels of virus (HCV RNA) at the start of the anemia management intervention were the same – 86 percent – among patients who had ribavirin dose reduction (111/129) and patients who received EPO (107/124). Additionally, the SVR rates for patients with detectable levels of HCV RNA at the start of intervention were the same – 56 percent – among patients who had ribavirin dose reduction (67/120) and patients who received EPO (71/127).
Anemia management interventions in cirrhotic patients
In another sub-analysis of the study, nine percent (60/664) of patients with available central pathology biopsy results were cirrhotic (METAVIR fibrosis score of F4). Of these, 80 percent (48/60) met the protocol definition for anemia and were randomized to one of the two anemia management strategies.
Of the patients requiring an anemia management strategy, the rates of SVR in the ribavirin dose reduction arm were 57 percent (13/23) in cirrhotic patients and 73 percent (162/221) in non-cirrhotic patients, while the rates of SVR in the EPO arm were 64 percent (16/25) in cirrhotic patients and 72 percent (157/217) in non-cirrhotic patients.
A higher percentage of cirrhotic patients received secondary interventions for anemia management than non-cirrhotic patients at 44 percent (21/48) and 26 percent (114/438), respectively.
This sub-analysis was limited by a small sample size of patients with cirrhosis, and the study was not stratified by cirrhotic versus non-cirrhotic patients.
In the sub-analysis evaluating anemia management strategies in cirrhotic patients, the most common adverse events occurring in 25 percent or more of either cirrhotic or non-cirrhotic patients were fatigue, anemia, nausea, diarrhea, dysguesia (bad taste), headache, neutropenia, alopecia, chills, dizziness, decreased appetite, insomnia and influenza-like illness.
Cirrhotic patients were more likely to develop lower platelet counts than non-cirrhotic patients.
Serious adverse events occurred in 20 percent of cirrhotic patients and 12 percent of non-cirrhotic patients. The discontinuation rates due to any adverse event were 17 and 16 percent, respectively. One non-cirrhotic patient who had multiple cardiac risk factors died of sudden cardiac arrest 23 days after discontinuing study drugs.
Merck's global commitment to advancing hepatitis therapy
Merck is committed to building on its strong legacy in the field of viral hepatitis by continuing to discover, develop and deliver vaccines and medicines to help prevent and treat viral hepatitis. In hepatitis C, company researchers developed the first approved therapy for chronic HCV in 1991 and the first combination therapy in 1998. In addition to ongoing studies with VICTRELIS, extensive research efforts are underway to develop additional oral therapies for viral hepatitis treatment.
Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.
This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such statements may include, but are not limited to, statements about the benefits of the merger between Merck and Schering-Plough, including future financial and operating results, the combined company’s plans, objectives, expectations and intentions and other statements that are not historical facts. Such statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements.
The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the possibility that all of the expected synergies from the merger of Merck and Schering-Plough will not be realized, or will not be realized within the expected time period; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; Merck’s ability to accurately predict future market conditions; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation and/or regulatory actions.
Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2011 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
Please see Prescribing Information for VICTRELIS® (boceprevir) at http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_pi.pdf and Medication Guide for VICTRELIS at http://www.merck.com/product/usa/pi_circulars/v/victrelis/victrelis_mg.pdf.
1 SVR, the protocol specified primary efficacy endpoint of the study, is defined as achievement of undetectable HCV-RNA at 24 weeks after the end of treatment in all randomized patients treated with any study medication. Per protocol, if a patient did not have a 24-week post-treatment assessment, the patient’s 12-week post-treatment assessment was utilized.
VICTRELIS™is a trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
Revatio® and Adcirca® are trademarks of their respective owners and are not trademarks of Merck & Co., Inc., Whitehouse Station, N.J., USA.
Copyright © 2009- Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. All rights reserved.
This website of Merck & Co., Inc., Kenilworth, NJ, USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.
Risks and uncertainties include, but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and healthcare legislation in the United States and internationally; global trends toward healthcare cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.
The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2015 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).
The information contained in this website was current as of the date presented. The company assumes no duty to update the information to reflect subsequent developments. Consequently, the company will not update the information contained in the website and investors should not rely upon the information as current or accurate after the presentation date.
Merck, known as MSD outside the United States and Canada, is a leading research-driven healthcare company.
Algeria – French
Argentina – Spanish
Australia – English
Austria – German
Belgium – Dutch, French, English
Brazil – Portuguese
Bulgaria – Bulgarian
Canada – French, English
Caribbean – English
Central America – Spanish
Chile – Spanish
China – Simplified Chinese
Colombia – Spanish
Costa Rica – Spanish
Croatia – Croatian
Czech Republic – Czech
Denmark – Danish
Dominican Republic – Dominican
Ecuador – Spanish
Egypt – English
Estonia – Estonian
Finland – Finnish
France – French
Fulford India – English
Germany – German
Greece – Greek
Gulf – English
Hong Kong – Chinese, English
Hungary – Hungarian
India – English
Indonesia – English
Ireland – English
Israel – Hebrew
Italy – Italian
Japan – Japanese
Latvia – Latvian
Lebanon – English
Lithuania – Lithuanian
Malaysia – English
Mexico – Spanish
Montenegro – Serbian
Netherlands – Dutch
New Zealand – English
Norway – Norwegian
Peru – Spanish
Philippines – English
Poland – Polish
Portugal – Portuguese
Puerto Rico – Spanish, English
Romania – Romanian, English
Russia – Russian
Saudi Arabia – English
Serbia – Serbian
Singapore – English
Slovakia – Slovak
Slovenia – Slovene
South Africa – English
South Korea – Korean
Spain – Spanish
Sweden – Swedish
Switzerland – English, French, German
Taiwan – Traditional Chinese
Thailand – Thai, English
Turkey – Turkish
Ukraine – Ukrainian
United Kingdom – English
United States – English
Venezuela – Spanish
Vietnam – Vietnamese